J Korean Neurosurg Soc.  2019 May;62(3):361-365. 10.3340/jkns.2019.0078.

Epilepsy Surgery in 2019: A Time to Change

• Phi JH
• Cho BK

• KMID: 2453242
• DOI: http://doi.org/10.3340/jkns.2019.0078

Abstract

Epilepsy has been known to humankind since antiquity. The surgical treatment of epilepsy began in the early days of neurosurgery and has developed greatly. Many surgical procedures have stood the test of time. However, clinicians treating epilepsy patients are now witnessing a huge tide of change. In 2017, the classification system for seizure and epilepsy types was revised nearly 36 years after the previous scheme was released. The actual difference between these systems may not be large, but there have been many conceptual changes, and clinicians must bid farewell to old terminology. Paradigms in drug discovery are changing, and novel antiseizure drugs have been introduced for clinical use. In particular, drugs that target genetic changes harbor greater therapeutic potential than previous screening-based compounds. The concept of focal epilepsy has been challenged, and now epilepsy is regarded as a network disorder. With this novel concept, stereotactic electroencephalography (SEEG) is becoming increasingly popular for the evaluation of dysfunctioning neuronal networks. Minimally invasive ablative therapies using SEEG electrodes and neuromodulatory therapies such as deep brain stimulation and vagus nerve stimulation are widely applied to remedy dysfunctional epilepsy networks. The use of responsive neurostimulation is currently off-label in children with intractable epilepsy.

Keyword

Epilepsy; Surgery; History

MeSH Terms

Child
Classification
Deep Brain Stimulation
Drug Discovery
Drug Resistant Epilepsy
Electrodes
Electroencephalography
Epilepsies, Partial
Epilepsy*
Humans
Neurons
Neurosurgery
Seizures
Vagus Nerve Stimulation

Reference

References

1. Catenoix H, Bourdillon P, Guénot M, Isnard J. The combination of stereo-EEG and radiofrequency ablation. Epilepsy Res. 142:117–120. 2018.

2. Cobourn K, Fayed I, Keating RF, Oluigbo CO. Early outcomes of stereoelectroencephalography followed by MR-guided laser interstitial thermal therapy: a paradigm for minimally invasive epilepsy surgery. Neurosurg Focus. 45:E8. 2018.

3. Engel J Jr. Classifications of the International League Against Epilepsy: time for reappraisal. Epilepsia. 39:1014–1017. 1998.

4. Feindel W, Leblanc R, de Almeida AN. Epilepsy surgery: historical highlights 1909-2009. Epilepsia. 50 Suppl 3:131–151. 2009.

5. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for classification and terminology. Epilepsia. 58:522–530. 2017.

6. Fuller-Thomson E, Brennenstuhl S. The association between depression and epilepsy in a nationally representative sample. Epilepsia. 50:1051–1058. 2009.

7. Geller EB. Responsive neurostimulation: review of clinical trials and insights into focal epilepsy. Epilepsy Behav. 88S:11–20. 2018.

8. Geller EB, Skarpaas TL, Gross RE, Goodman RR, Barkley GL, Bazil CW, et al. Brain-responsive neurostimulation in patients with medically intractable mesial temporal lobe epilepsy. Epilepsia. 58:994–1004. 2017.

9. Hachem LD, Wong SM, Ibrahim GM. The vagus afferent network: emerging role in translational connectomics. Neurosurg Focus. 45:E2. 2018.

10. Kaplan PW. Obsessive-compulsive disorder in chronic epilepsy. Epilepsy Behav. 22:428–432. 2011.

11. Klitgaard H, Verdru P. Levetiracetam: the first SV2A ligand for the treatment of epilepsy. Expert Opin Drug Discov. 2:1537–1545. 2007.

12. Kokoszka MA, Panov F, La Vega-Talbott M, McGoldrick PE, Wolf SM, Ghatan S. Treatment of medically refractory seizures with responsive neurostimulation: 2 pediatric cases. J Neurosurg Pediatr. 21:421–427. 2018.

13. Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol. 74:679–687. 2013.

14. Lee JH, Huynh M, Silhavy JL, Kim S, Dixon-Salazar T, Heiberg A, et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet. 44:941–945. 2012.

15. Lim JS, Gopalappa R, Kim SH, Ramakrishna S, Lee M, Kim WI, et al. Somatic mutations in TSC1 and TSC2 cause focal cortical dysplasia. Am J Hum Genet. 100:454–472. 2017.

16. Lim JS, Kim WI, Kang HC, Kim SH, Park AH, Park EK, et al. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. Nat Med. 21:395–400. 2015.

17. Loscher W. animal models of seizures and epilepsy: past, present, and future role for the discovery of antiseizure drugs. Neurochem Res. 42:1873–1888. 2017.

18. Minotti L, Montavont A, Scholly J, Tyvaert L, Taussig D. Indications and limits of stereoelectroencephalography (SEEG). Neurophysiol Clin. 48:15–24. 2018.

19. Ollivier I, Behr C, Cebula H, Timofeev A, Benmekhbi M, Valenti MP, et al. Efficacy and safety in frameless robot-assisted stereo-electroencephalography (SEEG) for drug-resistant epilepsy. Neurochirurgie. 63:286–290. 2017.

20. Reif PS, Strzelczyk A, Rosenow F. The history of invasive EEG evaluation in epilepsy patients. Seizure. 41:191–195. 2016.

21. Rho JM, White HS. Brief history of anti-seizure drug development. Epilepsia Open. 3(Suppl Suppl 2):114–119. 2018.

22. Rosenow F, Lüders H. Presurgical evaluation of epilepsy. Brain. 124(Pt 9):1683–1700. 2001.

23. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for classification and terminology. Epilepsia. 58:512–521. 2017.

24. Schijns OE, Hoogland G, Kubben PL, Koehler PJ. The start and development of epilepsy surgery in Europe: a historical review. Neurosurg Rev. 38:447–461. 2015.

25. Scholly J, Staack AM, Kahane P, Scavarda D, Regis J, Hirsch E, et al. Hypothalamic hamartoma: epileptogenesis beyond the lesion? Epilepsia. 58 Suppl 2:32–40. 2017.

26. Scoville WB, Milner B. Loss of recent memory after bilateral hippocampal lesions. J Neurol Neurosurg Psychiatry. 20:11–21. 1957.

27. Shorvon S, Schmidt D. The right and the wrong with epilepsy and her science. Epilepsia Open. 1:76–85. 2016.

28. Spencer DD, Gerrard JL, Zaveri HP. The roles of surgery and technology in understanding focal epilepsy and its comorbidities. Lancet Neurol. 17:373–382. 2018.

29. Taussig D, Chipaux M, Fohlen M, Dorison N, Bekaert O, Ferrand-Sorbets S, et al. Invasive evaluation in children (SEEG vs subdural grids). Seizure. 2018; [Epub ahead of print].

30. Wiebe S, Blume WT, Girvin JP, Eliasziw M, Efficiency of Surgery for Temporal Lobe Epilepsy Study Group. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med. 345:311–318. 2001.

31. Yu T, Wang X, Li Y, Zhang G, Worrell G, Chauvel P, et al. High-frequency stimulation of anterior nucleus of thalamus desynchronizes epileptic network in humans. Brain. 141:2631–2643. 2018.

32. Zifkin BG, Avanzini G. Clinical neurophysiology with special reference to the electroencephalogram. Epilepsia. 50 Suppl 3:30–38. 2009.

33. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. The Vagus Nerve Stimulation Study Group. Neurology. 45:224–230. 1995.

34. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 30:389–399. 1989.

35. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 22:489–501. 1981.